Private Trust Co. NA cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.6% during the 2nd quarter, HoldingsChannel reports. The firm owned 40,571 shares of the company’s stock after selling 1,499 shares during the quarter. Johnson & Johnson comprises about 0.6% of Private Trust Co. NA’s portfolio, making the stock its 23rd largest holding. Private Trust Co. NA’s holdings in Johnson & Johnson were worth $6,197,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Apexium Financial LP raised its holdings in Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after purchasing an additional 2,310 shares during the period. Avanza Fonder AB raised its holdings in Johnson & Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after purchasing an additional 6,566 shares during the period. Joel Isaacson & Co. LLC raised its holdings in Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after purchasing an additional 2,526 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its holdings in Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock worth $12,164,000 after purchasing an additional 4,816 shares during the period. Finally, Absher Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 1.2% during the first quarter. Absher Wealth Management LLC now owns 215,584 shares of the company’s stock worth $35,752,000 after acquiring an additional 2,469 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Johnson & Johnson
In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.
Analyst Ratings Changes
View Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Stock Up 0.6%
Shares of JNJ stock opened at $193.27 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.40. The firm’s fifty day moving average price is $180.49 and its two-hundred day moving average price is $164.86. The firm has a market capitalization of $465.45 billion, a P/E ratio of 18.65, a PEG ratio of 2.27 and a beta of 0.40.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The firm had revenue of $24.02 billion for the quarter. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
- Five stocks we like better than Johnson & Johnson
- What is the Dow Jones Industrial Average (DJIA)?
- Johnson & Johnson’s M&A Strategy Is the Real Story for Investors
- Investing In Preferred Stock vs. Common Stock
- Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.